Article info

Download PDFPDF

Extended report
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Authors

  1. Correspondence to Professor Edward C Keystone, The Rebecca MacDonald Centre for Arthritis & Autoimmune Disease, Mount Sinai Hospital, 60 Murray Street, Room 2-006, Box 4, Toronto, Ontario M5T 3L9, Canada; edkeystone{at}mtsinai.on.ca
View Full Text

Citation

Keystone EC, Taylor PC, Drescher E, et al
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Publication history

  • Received August 14, 2014
  • Revised November 4, 2014
  • Accepted November 7, 2014
  • First published November 27, 2014.
Online issue publication 
January 07, 2015

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.